Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD38 A2 CAR2-expressing T cells

A preparation of genetically modified autologous T cells expressing a chimeric antigen receptor recognizing the tumor-associated antigen (TAA) cluster of differentiation 38 (CD38), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD38 A2 CAR2-expressing T cells are directed to and induce selective toxicity in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.
Synonym:autologous anti-CD38 A2 CAR2 T cells
autologous CAR2 anti-CD38 A2 CAR T cells
autologous CAR2 anti-CD38 A2 T lymphocytes
autologous CD38-A2 CAR2-expressing T lymphocytes
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search